All Posts:News Release
-
Georgetown Investigator Presents Final PAPILLON Trial Results Showing Long-Term Survival in a Subset of Lung Cancer
Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.
Category: News Release
-
Lombardi Women Marks 20 Years of Supporting Breast Cancer Research; Honors Real Estate Entrepreneur and Breast Cancer Survivor Jessica Miller
Lombardi Women, a philanthropic community that supports breast cancer research at Georgetown Lombardi, has named Jessica Miller, a commercial real estate leader, entrepreneur, breast cancer survivor and advocate, as the recipient of its 2026 Spirit of Life Award.
Category: News Release
-
Preoperative Dual Immunotherapy Combination Shows Promising Activity in High-Risk Early-Stage HER2-Negative Breast Cancer
A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform.
Category: News Release
-
Despite Medicare Coverage, Many Cancer Patients Still Do Not Receive Testing That Guides Treatment Options
While there has been a recent increase among Medicare recipients in genomic testing that helps match cancer patients to the most effective treatment for their tumor, many Medicare beneficiaries with cancer are still not receiving next-generation sequencing, according to a new analysis by Georgetown University researchers.
Category: News Release
-
Study Reveals Why Breast Cancer Becomes More Deadly with Age
Researchers at Georgetown’s Lombardi Comprehensive Cancer Center have identified a mechanism that may help explain a key reason why older people experience worse outcomes from breast cancer. The study implicates RAGE (Receptor for Advanced Glycation End-products), a cell surface receptor that amplifies inflammatory signaling, and which also becomes increasingly active with metastatic progression.
Category: News Release
-
Study Finds Teen Perceptions of Sun Protection and Tanning Shape Skin Cancer Risk Behaviors
A new study from Georgetown Lombardi researchers finds that how high school students perceive the costs of sun protection and the rewards of tanning play a significant role in whether they practice sun-safe behaviors.
Category: News Release
-
New Study Examines Stigma Toward Women Who Lose Weight Using GLP-1 Medications
In a new study exploring stigma associated with the use of GLP-1 drugs for weight loss, women who lost weight using GLP-1 medications were judged more harshly than those who lost weight through diet and exercise, with negative reactions driven largely by beliefs that medication-assisted weight loss is a “shortcut.” The study also found higher levels of stigma when the women in sample scenarios were portrayed as White rather than Black.
Category: News Release
-
Dual Role of a Protein in Driving Bone Cancer in Children Discovered
Scientists at Georgetown University’s Lombardi Comprehensive Cancer Center have uncovered a new dual function for a well-known cancer-related protein called ezrin. This finding could potentially open the door to new treatments for osteosarcoma, the most common bone cancer in children and young adults, as well as other cancers that are ezrin-dependent.
Category: News Release
-
Louis M. Weiner, MD, to Step Down as Director of Georgetown’s Lombardi Comprehensive Cancer Center Following 18 Years of Leadership
After more than 18 years leading Georgetown University’s Lombardi Comprehensive Cancer Center, Louis M. Weiner, MD, has announced his decision to step down later this year.
Category: News Release
-
Reversing Immune Suppression in Pancreatic Cancer Could Lead to Novel Therapies
Georgetown Lombardi researchers discovered that when pancreatic cancer cells send out tiny particles that are packed with certain microRNA molecules, nearby immune cells called macrophages are reprogrammed to help the tumor grow instead of engaging in their regular role of fighting the tumor. This insight from cell and mouse experiments has helped the scientists outline a potential way to reverse the process and possibly improve outcomes in pancreatic cancer.
Category: News Release